The Work You Did Was Not Wasted. The Plan Just Changed.
If your business spent the past several months building a November 12 compliance plan — auditing your product line, testing lots, renegotiating supplier agreements, preparing for a significant market contraction — the Continuing Resolution extension through December 11 does not make that work irrelevant. It changes the timeline and the immediate stakes, but the compliance infrastructure you built has real and lasting value.
Here's how to recalibrate your compliance planning in light of the CR extension.
What November 12 Was Requiring (and Now Isn't)
The November 12 regulatory framework that the CR blocked would have required:
Total THC testing rather than Delta-9 THC testing. Products that passed under Delta-9-only testing may have failed under total THC calculations that include Delta-8, Delta-10, THCA converted to THC, and other isomers.
DEA-registered laboratory testing. All hemp testing would have been required to use DEA-registered laboratories, a capacity-constrained requirement that created significant practical challenges for the industry.
More restrictive serving size limits. The 0.4mg THC per serving / 2mg per package limits proposed under the November 12 framework would have eliminated a large portion of the current hemp product market.
Synthetic cannabinoid prohibition. Products containing certain chemically modified cannabinoids would have been categorically prohibited.
None of these requirements take effect as of November 12. The CR preserved the current framework, meaning the testing standards, THC limits, and laboratory requirements currently in place continue through December 11.
How to Adjust Your Compliance Plan
Keep your compliant product line intact. If you reformulated, retested, or adjusted products to be compliant under the November 12 standards, those products are also compliant under the current framework. There is no reason to reverse that work.
Pause discontinuation decisions. If you were planning to discontinue products that could not meet November 12 standards, hold those decisions until you have better visibility on what the December 11 permanent framework will look like. A product that couldn't meet November 12 standards might be viable under a different permanent framework.
Maintain your testing cadence. The current testing requirements remain in place through December 11. Continue testing against current standards. Do not reduce testing frequency based on the assumption that the extension means reduced scrutiny.
Keep your documentation current. COAs, batch records, supplier certifications, and product documentation should continue to be maintained at the same standard as before the CR extension. This documentation will matter for any audit or enforcement action regardless of which framework governs.
Continue supplier qualification work. If you were qualifying backup suppliers or tightening supplier agreements, that work has permanent value independent of any specific regulatory deadline.
New Planning Priorities Created by the Extension
The CR extension creates several planning priorities that weren't on your pre-extension radar:
December 11 scenario planning. Develop explicit plans for the three possible December 11 outcomes: permanent legislation, another extension, or expiration without new legislation. Each has different operational implications.
Q4 inventory strategy. The extension gives you a runway for Q4 stocking that November 12 would have cut short. Evaluate your Q4 inventory needs now, while the supply chain is open and pricing is favorable.
Product launch reconsideration. Products that were shelved due to November 12 uncertainty can be reconsidered for Q4 launch within the protected window.
Retailer and partner communication. Your retail partners, distributors, and customers may have made their own plans based on November 12. Proactively communicate the extension and what it means for product availability and your supply commitments.
The Compliance Posture That Serves You Regardless of Outcome
The most resilient compliance posture through December 11 — and beyond — is one that would hold up under any of the likely permanent framework outcomes:
- Naturally derived cannabinoids with documented hemp-derived starting materials
- Full-panel COA testing from accredited laboratories
- Clear THC potency documentation at both ingredient and finished product levels
- Supplier agreements that require compliance documentation
- Batch records that can support any product inquiry
This is not the most aggressive possible posture, but it is the most durable. It protects your business whether the permanent framework closely resembles today's rules, adopts some version of the November 12 standards, or lands somewhere in between.
Low Gravity Hemp supplies hemp ingredients that meet this compliance standard. Full-panel COAs, documented starting materials, deep Q4 inventory, and new bulk pricing. Same-day answers. Contact us to build your Q4 supply on a foundation that holds up under any regulatory outcome.
